Bufomix Easyhaler, 320 micrograms/9 micrograms/inhalation, inhalation powder Malta - Engels - Medicines Authority

bufomix easyhaler, 320 micrograms/9 micrograms/inhalation, inhalation powder

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 9 µg budesonide 320 µg - drugs for obstructive airway diseases

Bufar Easyhaler Inhalation Powder 160/4.5mcg/inhalatio Malta - Engels - Medicines Authority

bufar easyhaler inhalation powder 160/4.5mcg/inhalatio

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 4.5 µg budesonide 160 µg - drugs for obstructive airway diseases

Bufar Easyhaler Inhalation Powder 320/9 mcg/inhalation Malta - Engels - Medicines Authority

bufar easyhaler inhalation powder 320/9 mcg/inhalation

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 9 µg budesonide 320 µg - drugs for obstructive airway diseases

FOSTER 1006 Israël - Engels - Ministry of Health

foster 1006

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/dose; beclometasone dipropionate anhydrous 100 mcg/dose - formoterol and beclometasone - beclometasone - foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.copd :symptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

DUAKLIR PRESSAIR- aclidinium bromide and formoterol fumarte powder, metered Verenigde Staten - Engels - NLM (National Library of Medicine)

duaklir pressair- aclidinium bromide and formoterol fumarte powder, metered

circassia pharmaceuticals inc. - aclidinium bromide (unii: uqw7uf9n91) (aclidinium - unii:k17vy42f6c), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - duaklir pressair is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a laba) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd). limitations of use : duaklir pressair is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.4)] . use of a long-acting beta2 -adrenergic agonist (laba), including formoterol fumarate, one of the active ingredients in duaklir pressair, without an inhaled corticosteroid is contraindicated in patients with asthma [see warnings and precautions (5.1)] . duaklir pressair is not indicated for the treatment of asthma. duaklir pressair is contraindicated in patients with: risk summary there are no adequate and well-controlled studies of duaklir pressair or its individual components, formoterol fumarate or aclidinium bromide, in pregnant women to inform drug-associated risks. no adverse developmental effects were seen w

FOSTER 2006 Israël - Engels - Ministry of Health

foster 2006

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/actuation; beclometasone dipropionate anhydrous 200 mcg/actuation - formoterol and beclometasone - foster 200/6 is indicated in the regular treatment of asthma in adults where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.

Oxis Turbohaler 6 Powder for Inhalation 6mcg Malta - Engels - Medicines Authority

oxis turbohaler 6 powder for inhalation 6mcg

astrazeneca ab se-151 85, södertälje, sweden - formoterol fumarate, dihydrate - inhalation powder - formoterol fumarate dihydrate 4.5 µg - drugs for obstructive airway diseases

Oxis Turbohaler 12 Powder for Inhalation 12mcg Malta - Engels - Medicines Authority

oxis turbohaler 12 powder for inhalation 12mcg

astrazeneca ab se-151 85, södertälje, sweden - formoterol fumarate, dihydrate - inhalation powder - formoterol fumarate dihydrate 9 µg - drugs for obstructive airway diseases

SYMBICORT TURBUHALER 804.5 MCGDOSE Israël - Engels - Ministry of Health

symbicort turbuhaler 804.5 mcgdose

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - powder for inhalation - budesonide micronized 80 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. note: symbicort turbuhaler 80/4.5 mcg/dose is not appropriate in patients with severe asthma.